A recent randomized, double-blind, placebo-controlled clinical trial has shown that a proprietary gut health supplement containing N-trans caffeoyltyramine (NCT) and N-trans feruloyltyramine (NFT) significantly improves intestinal barrier function and gastrointestinal symptoms in individuals with diarrhea-predominant irritable bowel syndrome (IBS-D). Over a 3-week intervention, participants receiving 120 mg of NCT/NFT daily demonstrated significant reductions in intestinal permeability as measured by the Lactulose/Mannitol (L/M) ratio (p = 0.048), lipopolysaccharide-binding protein (LBP) levels (p = 0.018), and abdominal distension scores on the IBS Symptom Severity Scale (IBS-SSS) (p = 0.044) compared to placebo. The study, which reported no adverse events, is among the first to clinically validate the role of NCT and NFT in gut barrier restoration using both objective biomarkers and subjective symptom outcomes, supporting their potential as novel bioactives for managing gut barrier dysfunction in IBS-D.
Source: https://www.ffhdj.com/index.php/BioactiveCompounds/article/view/1655
